CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study...
Phase 1
Tampa, Florida, United States and 4 other locations
(a modified herpes simplex 1 virus that can specifically destroy cancer cells while leaving normal cells alone) injected directly into the t ...
Phase 1, Phase 2
Tampa, Florida, United States
with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metast...
Phase 1, Phase 2
Tampa, Florida, United States
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...
Phase 1, Phase 2
Tampa, Florida, United States and 49 other locations
oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoin ...
Phase 2
Tampa, Florida, United States and 23 other locations
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Tampa, Florida, United States and 165 other locations
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...
Phase 2
Tampa, Florida, United States and 13 other locations
the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase.* Cohort A: Advanced or Metastatic Triple Negative...
Phase 1, Phase 2
Saint Petersburg, Florida, United States and 15 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Tampa, Florida, United States and 516 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Tampa, Florida, United States and 505 other locations
Clinical trials
Research sites
Resources
Legal